Medite Cancer Diagnostics Inc
Medite Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controll… Read more
Market Cap & Net Worth: Medite Cancer Diagnostics Inc (MDIT)
Medite Cancer Diagnostics Inc (PINK:MDIT) has a market capitalization of $8.67K ($8.67K) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #47480 globally and #14677 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Medite Cancer Diagnostics Inc's stock price $0.00 by its total outstanding shares 86723700 (86.72 Million).
Medite Cancer Diagnostics Inc Market Cap History: 2015 to 2025
Medite Cancer Diagnostics Inc's market capitalization history from 2015 to 2025. Data shows change from $99.73 Million to $8.67K (-63.09% CAGR).
Medite Cancer Diagnostics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Medite Cancer Diagnostics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.82x
Medite Cancer Diagnostics Inc's market cap is 3.82 times its annual revenue
169.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $99.73 Million | $9.89 Million | -$859.00K | 10.09x | N/A |
| 2016 | $44.23 Million | $9.24 Million | -$2.16 Million | 4.79x | N/A |
| 2017 | $26.02 Million | $6.81 Million | -$6.81 Million | 3.82x | N/A |
Competitor Companies of MDIT by Market Capitalization
Companies near Medite Cancer Diagnostics Inc in the global market cap rankings as of March 18, 2026.
Key companies related to Medite Cancer Diagnostics Inc by market ranking:
- Intuitive Surgical Inc (NASDAQ:ISRG): Ranked #98 globally with a market cap of $170.40 Billion USD.
- EssilorLuxottica Société anonyme (PINK:ESLOF): Ranked #263 globally with a market cap of $78.22 Billion USD.
- EssilorLuxottica S. A. (PA:EL): Ranked #362 globally with a market cap of $61.18 Billion USD ( €59.61 Billion EUR).
- Becton Dickinson and Company (NYSE:BDX): Ranked #472 globally with a market cap of $45.90 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #98 | Intuitive Surgical Inc | NASDAQ:ISRG | $170.40 Billion | $482.76 |
| #263 | EssilorLuxottica Société anonyme | PINK:ESLOF | $78.22 Billion | $265.00 |
| #362 | EssilorLuxottica S. A. | PA:EL | $61.18 Billion | €203.00 |
| #472 | Becton Dickinson and Company | NYSE:BDX | $45.90 Billion | $161.64 |
Medite Cancer Diagnostics Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, Medite Cancer Diagnostics Inc's market cap moved from $99.73 Million to $ 8.67K, with a yearly change of -63.09%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $8.67K | 0.00% |
| 2024 | $8.67K | 0.00% |
| 2023 | $8.67K | -98.99% |
| 2022 | $858.56K | +4850.00% |
| 2021 | $17.34K | -96.83% |
| 2020 | $546.36K | -52.63% |
| 2019 | $1.15 Million | -33.50% |
| 2018 | $1.73 Million | -93.33% |
| 2017 | $26.02 Million | -41.18% |
| 2016 | $44.23 Million | -55.65% |
| 2015 | $99.73 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Medite Cancer Diagnostics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.67K USD |
| MoneyControl | $8.67K USD |
| MarketWatch | $8.67K USD |
| marketcap.company | $8.67K USD |
| Reuters | $8.67K USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.